RE
GNMK

RBC Europe’s GenMark Diagnostics, Inc GNMK Stock Holding History

RBC Europe’s Portfolio GNMK Stock Details GNMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-50
Closed -$1.2K – 1265
2021
Q1 		$1.2K Hold
50
– – ﹤0.01% 1116
2020
Q4 		$730 Hold
50
– – ﹤0.01% 1100
2020
Q3 		$710 Hold
50
– – ﹤0.01% 1039
2020
Q2 		$736 Hold
50
– – ﹤0.01% 1005
2020
Q1 		$206 Sell
50
-5
-9% -$23 ﹤0.01% 1012
2019
Q4 		$265 Hold
55
– – ﹤0.01% 1020
2019
Q3 		$333 Hold
55
– – ﹤0.01% 1017
2019
Q2 		$357 Sell
55
-1,735
-97% -$12.2K ﹤0.01% 1037
2019
Q1 		$12.7K Sell
1,790
-2
-0.1% -$13 ﹤0.01% 759
2018
Q4 		$8.71K Hold
1,792
– – ﹤0.01% 826
2018
Q3 		$13.2K Hold
1,792
– – ﹤0.01% 782
2018
Q2 		$11.4K Hold
1,792
– – ﹤0.01% 824
2018
Q1 		$9.75K Hold
1,792
– – ﹤0.01% 838
2017
Q4 		$7.47K Buy
1,792
+1,735
+3,044% +$10.4K ﹤0.01% 888
2017
Q3 		$549 Buy
+57
New +$592 ﹤0.01% 1097

RBC Europe's GNMK Position: Q2 2021 in Review

RBC Europe sold out of GenMark Diagnostics, Inc (GNMK) in Q2 2021, closing a stake of 50 shares — an estimated $1.2K sold.

RBC Europe first reported a position in GNMK in Q3 2017 and held it in 15 quarters. The position peaked at $13.2K in Q3 2018. 0 funds tracked by Wall St. Rank hold GNMK as of Q2 2021.

  • RBC Europe reported no remaining GenMark Diagnostics, Inc position as of Q2 2021 after selling out during the quarter.
  • RBC Europe sold 50 GenMark Diagnostics, Inc shares in Q2 2021, an estimated $1.2K.
  • RBC Europe first reported a position in GenMark Diagnostics, Inc in Q3 2017 and held it in 15 quarters.
  • RBC Europe's GenMark Diagnostics, Inc position peaked at $13.2K in Q3 2018.
  • 0 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q2 2021.

Based on RBC Europe's 13F filing for Q2 2021, filed 9 Nov 2023.